Therapeutics Letter
- PMID: 38145549
- Bookshelf ID: NBK598434
Therapeutics Letter
Excerpt
This is a bimonthly publication targeting identified problematic therapeutic issues in a brief, simple and practical manner.
The process leading up to publication involves a rigorous, systematic literature review by different working groups of the Therapeutics Initiative, the creation of a draft which is circulated for comment among a sizeable group of over 100 local, national and international specialists with expertise in the particular therapeutic area and the commission of original artwork/illustration.
The message is developed collaboratively by different working groups of the Therapeutics Initiative. The current Editor in Chief is Dr. Tom Perry, Chair of the
Therapeutics Letters on common therapies have been regularly published since 1994 and distributed free of charge to clinicians, patients, and policymakers to increase awareness and improve prescription habits.
Copyright © 1994 - 2022 Therapeutics Initiative, University of British Columbia.
Sections
- Letter 158. Improving how we prescribe zopiclone and trazodone for insomnia
- Letter 157. How to stop antidepressants
- Letter 156. Antidepressant withdrawal syndrome - Update
- Letter 155. Oral vs IV antibiotics
- Letter 154. Thyroid testing in primary hypothyroidism
- Letter 153. Triple therapy for COPD: Understanding evidence is complicated
- Letter 152. Avoid serotonergic antidepressants for people with alcohol and other substance use disorders
- Letter 151. Minimizing harms of tight glycemic control in older people with type 2 diabetes
- Letter 150. Emergency contraceptives: Which pill will you recommend?
- Letter 149. How useful is Paxlovid™ in 2024?
- Letter 148. Rethink clindamycin for dental patient safety
- Letter 147. Screening to reduce fragility fractures: new trials, still ineffective
- Letter 146. Apixaban is safer and more effective than rivaroxaban for non-valvular atrial fibrillation
- Letter 145. Minimizing inhaled corticosteroids for COPD
- Letter 144. ADHD in adults
- Letter 143. Reducing the adverse environmental impacts of prescribing
- Letter 142. Simple clinical pharmacology can improve prescribing
- Letter 141. Paxlovid in British Columbia Interim real-world analysis
- Letter 140. What to do about borderline hyperglycemia?
- Letter 139. How well do you know your dopamine antagonists?
- Letter 138. Reducing prescribing cascades
- Letter 137. Physical activity is medicine: Prescribe it
- Letter 136. How do YOU respond to Conflicts of Interest?
- Letter 135. Empiric Antibiotic Therapy for Uncomplicated Lower Urinary Tract Infections
- Letter 134. Finding the lowest effective dose for non-opioid analgesics
- Letter 133. Primary hypertension therapy: after thiazide, an ACEI or an ARB?
- Letter 132. Rethinking: Medication Adherence
- Letter 131. Tramadol: Where do we go from here?
- Letter 130. Evidence for statins in people over 70
- Letter 129. Mirtazapine: Update on efficacy, safety, dose response
- Letter 128. Drug Safety Advisories: A need for international coordination
- Letter 127. Audit and Feedback: Personal Prescribing Portrait
- Letter 126. Serious harms with long-term PPI use in older adults
- Letter 125. Can prescribers avoid contributing to opioid use disorder?
- Letter SE. Pill splitting: Making the most of meds in a time of need
- Letter 124. Your views of the Therapeutics Initiative: 2019 Survey
- Letter 123. Biosimilars or Biologics: What’s the difference?
- Letter 122. Twenty-Five Pearls from 25 years (part 2)
- Letter 121. Twenty-Five Pearls from 25 years (part 1)
- Letter 120. Routine VTE prophylaxis: Is there a net health benefit?
- Letter 119. Epinephrine autoinjectors available in Canada
- Letter 118. Trends in utilization of proton pump inhibitors in British Columbia
- Letter 117. Gabapentin and pregabalin: Are high doses justified?
- Letter 116. New drug for cystic fibrosis: Regulatory approval, clinical uncertainty?
- Letter 115. Cannabinoids for Chronic Pain
- Letter 114. Shingrix: A New Vaccine for Shingles
- Letter 113. How well do you know your anticholinergic (antimuscarinic) drugs?
- Letter 112. Antidepressant Withdrawal Syndrome
- Letter 111. Deprescribing Proton Pump Inhibitors
- Letter 110. Stimulants for ADHD in children: Revisited
- Letter 109. Inhaled long acting β2 agonists for COPD
- Letter 108. Drugs to avoid
- Letter 107. EMPA-REG OUTCOME Trial What does it mean?
- Letter 106. Using Best Evidence for the Management of Hypertension
- Letter 105. Is cyclobenzaprine useful for pain?
- Letter 104. Does Medication Review improve health?
- Letter 103. Is the current ‘glucocentric’ approach to management of type 2 diabetes misguided?
- Letter 102. Indacaterol for chronic obstructive pulmonary disease
- Letter 101. Study 329: Why is it so important?
- Letter 100. Questioning the basis of approval for non-insulin glucose lowering drugs
- Letter 99. Comparative effectiveness of proton pump inhibitors
- Letter 98. Does SPRINT change our approach to blood pressure targets?
- Letter 97. Intravenous (IV) iron for severe iron deficiency
- Letter 96. Benefits and harms of drugs for “neuropathic” pain
- Letter 95. Antipsychotics should not be used for non-psychotic depression
- Letter 94. Dual antiplatelet therapy: net health benefit or harm?
- Letter 93. Are claims for newer drugs for overactive bladder warranted?
- Letter 92. The limitations and potential hazards of using surrogate markers
- Letter 91. Is prescribing information from sales representatives balanced?
- Letter 90. Reducing polypharmacy: A logical approach
- Letter 89. Statins proven and associated harms
- Letter 88. Filling the Evidence Gap Pragmatic Randomized Controlled Trials in British Columbia
- Letter 87. High dose versus standard dose statins in stable coronary heart disease
- Letter 86. Your opinions of the Therapeutics Initiative: The 2011 Survey
- Letter 85. Clinical Pearls from Prescrire
- Letter 84. A Systematic Review of the Harms of Bisphosphonates
- Letter 83. A Systematic Review of the Efficacy of Bisphosphonates
- Letter 82. Clinical Hypertension Pearls from The Cochrane Library
- Letter 81. Self-Monitoring of Blood Glucose in Type 2 Diabetes
- Letter 80. Dabigatran for atrial fibrillation Why we can not rely on RE-LY
- Letter 79. Is use of quetiapine for sleep evidence-based?
- Letter 78. Bisphosphonates: Do they prevent or cause bone fractures?
- Letter 77. Do statins have a role in primary prevention? An update
- Letter 76. Are antidepressants safe in pregnancy? A focus on SSRIs
- Letter 75. Gabapentin for pain: New evidence from hidden data
- Letter 74. Increasing use of newer antipsychotics in children: A cause for concern?
- Letter 73. Atomoxetine for ADHD in children and adolescents
- Letter 72. Prescription drug costs: BC versus Canada
- Letter 71. Treatment of elevated blood pressure in the very elderly Less is better
- Letter 70. Clinical Pearls from the most popular Cochrane reviews in 2007
- Letter 69. What is the evidence for using CNS stimulants to treat ADHD in children?
- Letter 68. Glycemic Targets in Type 2 Diabetes
- Letter 67. Evaluating the Media as a source of Drug Therapy Information
- Letter 66. Is newer better? New drugs for treatment of overactive bladder
- Letter 65. Clinical implications of recent key therapeutic trials
- Letter 64. Your opinions of the Therapeutics Letter: The 2006 Survey
- Letter 63. Using Framingham for primary prevention cardiovascular risk assessment
- Letter 62. Mild Hypertension: An approach to using evidence in the decision making process
- Letter 61. What is the Common Drug Review?
-
Letter 60. Clinical Pearls from
Prescrire - Letter 59. Increasing Drug Costs: Are we getting good value?
- Letter 58. Benign Prostatic Hypertrophy: An update on drug therapy
- Letter 57. Drugs for Overactive Bladder Symptoms
- Letter 56. Drugs for Alzheimer’s Disease
- Letter 55. Clinical Pearls from The Cochrane Library
- Letter 54. Use of Benzodiazepines in BC Is it consistent with recommendations?
- Letter 53. Rofecoxib (Vioxx®) withdrawal generates uncertainty about “ COX-2s”: Do product monographs adequately inform?
- Letter 52. Antidepressant Medications in Children and Adolescents
- Letter 51. New Drugs VIII
- Letter 50. Can blood pressure be lowered by a change in diet? Evidence from the DASH trials
- Letter 49. Statin’s benefit for secondary prevention confirmed: What is the optimal dosing strategy?
- Letter 48. Do Statins have a Role in Primary Prevention?
- Letter 47. The Answer: Thiazides First-line for Hypertension
- Letter 46. Menopausal Combined Hormone Therapy Update
- Letter 45. Do Single Stereoisomer Drugs Provide Value?
- Letter 44. New Drugs VII
- Letter 43. COX-2 inhibitors update: Do journal publications tell the full story?
- Letter 42. Serious Adverse Event Analysis: Lipid-Lowering Therapy Revisited
- Letter 41. Asymptomatic Bacteriuria in Pregnancy: Rapid answers using the Cochrane Library
- Letter 40. Direct To Consumer Advertising: Finasteride for male pattern hair loss
- Letter 39. Selective COX-2 inhibitors: Are they safer NSAIDs?
- Letter 38. Prevention and Treatment of Influenza A and B
- Letter 37. Antiplatelet Chemoprevention of Occlusive Vascular Events and Death
- Letter 36. New Drugs VI
- Letter 35. Sources of Drug Therapy Information
- Letter 34. New Drugs V
- Letter 33. Treatment of Pain in the Older Patient
- Letter 32. Management of Erectile Dysfunction
- Letter 31. Celecoxib (Celebrex®): Is it a Breakthrough Drug?
- Letter 30. Levels of Evidence for Clinical Decisions: Menopausal Hormone Therapy Revisited
- Letter 29. Leukotriene Antagonists: What is their role in the management of ASTHMA?
- Letter 28. Angiotensin II Receptor Blockers: Their role in hypertension and congestive heart failure
- Letter 27. Review & Update 1998
- Letter 26. New Drugs IV
- Letter 25. Herbal Medicines: An Evidence Based Look
- Letter 24. Lipid Lowering Therapy
- Letter 23. Management of Type 2 Diabetes
- Letter 22. Treatment of Acute Migraine Headaches
- Letter 21. Effective Clinical Tobacco Intervention
- Letter 20. New Drugs III
- Letter 19. Medical Management of Benign Prostatic Hyperplasia
- Letter 18. Management of Anxiety Disorders in Primary Care
- Letter 17. New Drugs 2
- Letter 16. Review and Update 1996
- Letter 15. Evidence Based Drug Therapy: What Do the Numbers Mean?
- Letter 14. Menopausal Hormone Therapy
- Letter 13. New Drugs
- Letter 12. Changing Concepts in the Management of Asthma
- Letter 11. To Sleep or not to Sleep: Here are your Questions
- Letter 10. Dose Titration: Minimize to Maximize
- Letter 9. Review and Update
- Letter 8. Drugs of Choice in the Treatment of Hypertension: Part 2
- Letter 7. Drugs of Choice in the Treatment of Hypertension: Part 1
- Letter 6. Medical Management of Ischemic Heart Disease: The Optimal Use of Nitrates
- Letter 5. Anti-infective Guidelines for Community-Acquired Infections
- Letter 4. Should we be using NSAIDS for the treatment of Osteoarthritis and “Rheumatism”
- Letter 3. Treatment of Gastroesophageal Reflux Disease (GERD)
-
Letter 2. Definitive Treatment of Peptic Ulcer Disease by Eradication of Helicobacter Pylori
(H. pylori) - Letter 1. Treatment of Non-Ulcer Dyspepsia in Adults: Common Questions about H2-blockers
Publication types
LinkOut - more resources
Full Text Sources